Study Population. Five hundred eighteen patients, 5 to 12 years old with persistent asthma. Patients were receiving sodium cromoglycate, nedocromil sodium, and/or inhaled corticosteroids at stable doses for at least 1 month before entry in the study.
Purpose of the Study. Parents often report that nebulized albuterol makes their children "hyper."
Study Population. Nineteen children with asthma 25 to 64 months of age whose parents thought that albuterol made their children overactive.
Methods. This was a double-blind, crossover study with children randomized to receive nebulization with albuterol (5 mg) or saline, then the reverse [Note: the usual dose is 0.5 mL of the 0.5% solution ϭ 2.5 mg]. Behavior was rated by parents using Connors' Rating Scale at baseline and after nebulization. Professional observers rated the level of activity using Preschool Behavior Observation Scale (PS-BOS).
Results. Parental ratings of activity revealed no significant difference between baseline and postalbuterol scores. Professional observers ratings of activity revealed no evidence of an increase in the child's activity after administration of albuterol.
Conclusions. Neither parental report nor observer ratings suggested any significant increase in the child's level of activity after albuterol.
Reviewer's Comments. Although often reported, when studied in a blinded fashion, an albuterol nebulization, even 5 mg, does not cause preschoolers to be "hyper." Perhaps it is the setting (asthma attack) in which a nebulization is normally given that changes children's behavior or their parents perception thereof. Study Population. Study subjects were corticosteroidnaive individuals with mostly moderate persistent asthma who were 18 to 55 years of age. The study was designed as a feasibility study rather than a comparative trial.
Methods. Thirty subjects were randomized to receive either beclomethasone dipropionate (BDP) 168, 672, and 1344 g/day (n ϭ 15) or fluticasone propionate (FP) 88, 352, and 704 g (n ϭ 15) via metered-dose inhaler (MDI) with chlorofluorocarbon propellant and OptiChamber (Respironics, Cedar Grove, NJ) spacer in 3 consecutive 6-week intervals. Compliance was monitored with a Doser CT (Meditrack Products, Hudson, MA) device. All subjects then received 3 weeks of FP dry powder inhaler (DPI) 2000 g/day. The primary outcome variable for assessing comparative efficacy was forced expiratory volume in 1 second (FEV 1 ). Secondary outcomes were methacholine PC-20, exercise-induced change in FEV 1 , exhaled nitric oxide (eNO), and induced sputum eosinophilia. Overnight cortisol suppression was measured by collecting hourly blood samples from 7 pm to 7 am.
Results. Maximum FEV 1 response occurred with the lowest dose of FP and the medium dose of BDP and was not further increased by high-dose FP-DPI. Near-maximum improvement in methacholine PC-20 occurred with low-dose FP and medium-dose BDP. Responsiveness to ICS varied markedly among subjects. Good (Ͼ15%) FEV 1 response was associated with high eNO, high pretreatment bronchodilator reversibility, and low pretreatment forced expiratory volume in 1 second/forced vital capacity (FEV 1 /FVC) when compared with poor (Ͻ5%) FEV 1 response. Both BDP and FP caused dose-dependent cortisol suppression.
Conclusions. Near-maximum improvements in FEV 1 and methacholine PC-20 occurred with low doses of FP and medium doses of BDP in these subjects with moderate persistent asthma. Higher doses did not improve efficacy but directly increased systemic side effect, as measured by overnight cortisol secretion. When comparing different ICS in future studies, larger numbers of subjects will be necessary to better define dose-response relationships for both efficacy and side effects.
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